Journal of Clinical Oncology, Vol 9, 1453-1461, Copyright © 1991 by American Society of Clinical Oncology

ARTICLES

A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer

R Cellerino, D Tummarello, F Guidi, P Isidori, M Raspugli, B Biscottini and G Fatati
Department of Clinical Oncology, University of Ancona, Italy.

From April 1985 to September 1988, 128 patients with advanced non-small- cell lung cancer (NSCLC) were enrolled in a prospective randomized trial evaluating chemotherapy (arm A) versus best supportive care (arm B). Chemotherapy consisted of cyclophosphamide 500 mg/m2 intravenously (IV) day 1, epirubicin 50 mg/m2 IV day 1, and cisplatin 80 mg/m2 IV day 1 (CE'P regimen) alternating every 4 weeks with methotrexate 30 mg/m2 IV day 1, etoposide 200 mg/m2 IV day 1, and lomustine (CCNU) 70 mg/m2 orally day 1 (MEC' regimen) until progression. Of the 123 patients (62 treated and 61 controls) eligible for survival, 115 were fully evaluable for response (58 treated and 57 controls). Response rates were 21% partial response, 53% stable disease, and 26% progressive disease in arm A, and 47% stable disease and 53% progressive disease in arm B. Median survival was 34.3 weeks (range, 4.3 to 218.6+ weeks) in arm A versus 21.1 weeks (range, 4.3 to 188.6 weeks) in arm B; the difference was not significant at P = .153 (Mantel-Cox). Subgroups of patients retrospectively analyzed by age, performance status, stage M0/M1, and weight loss or not showed no significant difference in survival. Poor-risk patients (at least two of the following: poor performance status, stage M1, weight loss) of arm A survived significantly longer than poor-risk patients of arm B (23.6 weeks v 12.4 weeks, Mantel-Cox P = .008); a significant difference in survival was also observed between nonsquamous cell patients of arm A and those of arm B (median survival, 38.6 weeks v 16.7 weeks; Mantel-Cox P = .041). Toxicity on the chemotherapy arm was hematologic (World Health Organization [WHO] grade greater than 3) in 12% of CE'P and in 13% of MEC' courses and gastroenteric (WHO grade greater than 3) in 24% of CE'P courses and in 8% of MEC' courses. Our alternating treatment was not significantly superior to supportive care. It is likely that certain subgroups of the NSCLC category may have an advantage with chemotherapy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]

				G. V. Scagliotti, P. Ceppi, S. Novello, and M. Papotti Chemotherapy Treatment Decisions in Advanced Non-small Cell Lung Cancer Based on Histology ASCO Educational Book, January 1, 2009; 2009(1): 431 - 435. [Abstract] [Full Text] [PDF]

				NSCLC Meta-Analyses Collaborative Group Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials J. Clin. Oncol., October 1, 2008; 26(28): 4617 - 4625. [Abstract] [Full Text] [PDF]

				F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, and O. Belvedere Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature Oncologist, April 1, 2007; 12(4): 451 - 464. [Abstract] [Full Text] [PDF]

				T. D. Shanafelt, C. Loprinzi, R. Marks, P. Novotny, and J. Sloan Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer? J. Clin. Oncol., May 15, 2004; 22(10): 1966 - 1974. [Abstract] [Full Text] [PDF]

				E. B. Lamont and N. A. Christakis Complexities in Prognostication in Advanced Cancer: "To Help Them Live Their Lives the Way They Want to" JAMA, July 2, 2003; 290(1): 98 - 104. [Abstract] [Full Text] [PDF]

				G. Chvetzoff and I. F. Tannock Placebo Effects in Oncology J Natl Cancer Inst, January 1, 2003; 95(1): 19 - 29. [Abstract] [Full Text] [PDF]

				M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer Chest, January 1, 2003; 123(1_suppl): 226S - 243S. [Abstract] [Full Text] [PDF]

				Y. S. Choi, Y. M. Shim, J. Kim, and K. Kim Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 695 - 700. [Abstract] [Full Text] [PDF]

				A. W. Blackstock, J. E. Herndon II, E. D. Paskett, M. C. Perry, S. L. Graziano, J. J. Muscato, M. P. Kosty, W. L. Akerley, J. Holland, S. Fleishman, et al. Outcomes Among African-American/Non-African-American Patients With Advanced Non-Small-Cell Lung Carcinoma: Report From the Cancer and Leukemia Group B J Natl Cancer Inst, February 20, 2002; 94(4): 284 - 290. [Abstract] [Full Text] [PDF]

				J.-M. Berthelot, B. P. Will, W. K. Evans, D. Coyle, C. C. Earle, and L. Bordeleau Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 16, 2000; 92(16): 1321 - 1329. [Abstract] [Full Text] [PDF]

				C. C. Earle, L. N. Venditti, P. J. Neumann, R. D. Gelber, M. C. Weinstein, A. L. Potosky, and J. C. Weeks Who Gets Chemotherapy for Metastatic Lung Cancer? Chest, May 1, 2000; 117(5): 1239 - 1246. [Abstract] [Full Text] [PDF]

				D. H. Johnson Evolution of Cisplatin-Based Chemotherapy in Non-Small Cell Lung Cancer : A Historical Perspective and The Eastern Cooperative Oncology Group Experience Chest, April 1, 2000; 117(4_suppl_1): 133S - 137S. [Abstract] [Full Text] [PDF]

				A. B. Sandler, J. Nemunaitis, C. Denham, J. von Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, Ch. Manegold, M. C. Palmer, A. Gregor, et al. Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer J. Clin. Oncol., January 5, 2000; 18(1): 122 - 122. [Abstract] [Full Text] [PDF]